Your browser doesn't support javascript.
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort.
Gasparotto, Michela; Bindoli, Sara; Padoan, Roberto; Cozzi, Giacomo; Depascale, Roberto; Zanatta, Elisabetta; Giollo, Alessandro; Gatto, Mariele; Zen, Margherita; Schiavon, Franco; Ramonda, Roberta; Sfriso, Paolo; Doria, Andrea; Iaccarino, Luca.
  • Gasparotto M; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Bindoli S; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Padoan R; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Cozzi G; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Depascale R; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Zanatta E; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Giollo A; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Gatto M; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Zen M; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Schiavon F; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Ramonda R; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Sfriso P; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Doria A; Rheumatology Unit, Department of Medicine, University of Padova, Italy.
  • Iaccarino L; Rheumatology Unit, Department of Medicine, University of Padova, Italy. luca.iaccarino@unipd.it.
Clin Exp Rheumatol ; 2022 Aug 05.
Article in English | MEDLINE | ID: covidwho-2260239
ABSTRACT

OBJECTIVES:

Anti-COVID-19 vaccines have proved to be effective and well tolerated. Great attention is now being paid to the characterisation of possible adverse events associated to their administration. We report a case series of suspected rheumatic diseases (RDs) following anti-COVID-19 vaccination.

METHODS:

We included patients evaluated at first-aid rheumatologic consultancy and at rheumatologic outpatient and inpatient clinic at Padova University Hospital between May and September 2021 presenting with a RD within 30 days after an anti-COVID-19 vaccine dose. Our selection was in accordance with the World Health Organisation guidelines for adverse event following immunisation (AEFI) surveillance. Patients were regularly re-evaluated by telemedicine or face-to-face visit.

RESULTS:

We identified 30 cases of RD following vaccination 24 (80.0%) new onsets and 6 (20.0%) flares. Most of patients (76.6%) received the BNT162b2 vaccine. The mean time to RD onset/flare was 12±9 days. The most common manifestations were inflammatory arthritis (40.0%), rheumatic polymyalgia (33.3%) and adult-onset Still's disease (13.3%). At the last FU visit (9.6±2.2 months), 83.3% of patients showed complete response to first- or second-line therapy, 13.3% a partial response and one patient (3.3%) was still experiencing an active disease.

CONCLUSIONS:

Considering the amount of vaccine doses administered during the evaluation period we overall detected a limited number of cases. We noted a clear prevalence of autoinflammatory conditions and seronegative manifestations. The great majority of patients had mild features and showed a good response to therapy.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Clinexprheumatol

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Clinexprheumatol